Overview Dividends

(ALNY) Alnylam Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02043Q1076

ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio

Biotechnology
Market Cap in USD: 52,868m

IPO / Inception: 2004-05-28
Return 12m vs S&P 500: 40.3%

EPS (Earnings per Share)

EPS CAGR: 39.58%
EPS Trend: 72.8%

Last SUE: -2.44
Qual. Beats: 0

Revenue

Rev. CAGR: 52.20%
Rev. Trend: 91.0%

Last SUE: 2.10
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	53.5%
Value at Risk 5%th	75.4%
Relative Tail Risk	-14.32%

Reward TTM
Sharpe Ratio	1.32
Alpha	55.35
CAGR/Max DD	0.52

Character TTM
Hurst Exponent	0.500
Beta	0.906
Beta Downside	0.965

Drawdowns 3y
Max DD	39.15%
Mean DD	15.72%
Median DD	15.51%

Description: ALNY Alnylam Pharmaceuticals December 03, 2025

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a Cambridge-based biotech that commercializes RNA-interference (RNAi) medicines and runs an extensive pipeline targeting rare and common diseases. Its approved portfolio includes ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

The company’s late-stage pipeline features vutrisiran (Phase III for ATTR-cardiomyopathy), Fitusiran (Phase III for hemophilia), and cemdisiran (Phase III for myasthenia gravis, PNH, and geographic atrophy). Early-stage programs span metabolic, neuro-degenerative, and oncology indications, including ALN-HTT02 (Phase I Huntington’s disease) and ALN-SOD (Phase II ALS).

Key financial and market metrics (Q3 2024): revenue of $1.12 billion, driven primarily by Leqvio ($310 million) and ONPATTRO ($210 million); a 30 % year-over-year revenue growth rate; and a cash runway extending beyond 2027 under current spending levels. The RNAi therapeutic market is projected to expand at a ~15 % CAGR through 2030, positioning Alnylam as a leading beneficiary of both rare-disease premium pricing and emerging indications with larger patient populations.

Strategic collaborations with Regeneron, Roche, Sanofi, Novartis, and others provide co-development funding and broaden commercial reach, while the company’s 2024-2025 guidance assumes a 12-15 % increase in total sales, contingent on successful Phase III readouts and regulatory approvals.

For a deeper, data-driven assessment of Alnylam’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (43.6m TTM) > 0 and > 6% of Revenue (6% = 192.6m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 4.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 74.68% (prev 101.9%; Δ -27.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 265.9m > Net Income 43.6m (YES >=105%, WARN >=100%)

Net Debt (1.28b) to EBITDA (186.5m) ratio: 6.88 <= 3.0 (WARN <= 3.5)

Current Ratio 2.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (137.3m) change vs 12m ago 6.81% (target <= -2.0% for YES)

Gross Margin 83.99% (prev 85.37%; Δ -1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 70.89% (prev 49.82%; Δ 21.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.80 (EBITDA TTM 186.5m / Interest Expense TTM 162.3m) >= 6 (WARN >= 3)

Altman Z'' -3.01

(A) 0.49 = (Total Current Assets 3.95b - Total Current Liabilities 1.56b) / Total Assets 4.85b

(B) -1.48 = Retained Earnings (Balance) -7.16b / Total Assets 4.85b

warn (B) unusual magnitude: -1.48 — check mapping/units

(D) -1.56 = Book Value of Equity -7.18b / Total Liabilities 4.62b

Total Rating: -3.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.66

1. Piotroski 4.0pt

2. FCF Yield 0.42%

3. FCF Margin 6.90%

4. Debt/Equity 11.86

5. Debt/Ebitda 6.88

6. ROIC - WACC (= 2.47)%

7. RoE 26.13%

8. Rev. Trend 90.99%

9. EPS Trend 72.77%

What is the price of ALNY shares?

As of January 10, 2026, the stock is trading at USD 399.40 with a total of 1,385,467 shares traded.
Over the past week, the price has changed by -0.19%, over one month by -7.12%, over three months by -11.38% and over the past year by +66.04%.

Is ALNY a buy, sell or hold?

Alnylam Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALNY.

Strong Buy: 12
Buy: 12
Hold: 7
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the ALNY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	491.9	23.2%
Analysts Target Price	491.9	23.2%
ValueRay Target Price	462.4	15.8%

ALNY Fundamental Data Overview January 04, 2026

P/E Trailing = 1429.1786
P/E Forward = 44.843
P/S = 16.4694
P/B = 224.6105
P/EG = -0.49
Beta = 0.298
Revenue TTM = 3.21b USD
EBIT TTM = 130.2m USD
EBITDA TTM = 186.5m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 160.4m USD (from shortTermDebt, last quarter)
Debt = 2.77b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.28b USD (from netDebt column, last quarter)
Enterprise Value = 52.92b USD (52.87b + Debt 2.77b - CCE 2.72b)
Interest Coverage Ratio = 0.80 (Ebit TTM 130.2m / Interest Expense TTM 162.3m)
FCF Yield = 0.42% (FCF TTM 221.4m / Enterprise Value 52.92b)
FCF Margin = 6.90% (FCF TTM 221.4m / Revenue TTM 3.21b)
Net Margin = 1.36% (Net Income TTM 43.6m / Revenue TTM 3.21b)
Gross Margin = 83.99% ((Revenue TTM 3.21b - Cost of Revenue TTM 514.0m) / Revenue TTM)
Gross Margin QoQ = 84.21% (prev 81.52%)
Tobins Q-Ratio = 10.91 (Enterprise Value 52.92b / Total Assets 4.85b)
Interest Expense / Debt = 1.60% (Interest Expense 44.4m / Debt 2.77b)
Taxrate = -5.07% (negative due to tax credits) (-12.1m / 239.0m)
NOPAT = 136.8m (EBIT 130.2m * (1 - -5.07%)) [negative tax rate / tax credits]
Current Ratio = 2.54 (Total Current Assets 3.95b / Total Current Liabilities 1.56b)
Debt / Equity = 11.86 (Debt 2.77b / totalStockholderEquity, last quarter 233.9m)
Debt / EBITDA = 6.88 (Net Debt 1.28b / EBITDA 186.5m)
Debt / FCF = 5.80 (Net Debt 1.28b / FCF TTM 221.4m)
Total Stockholder Equity = 166.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.96% (Net Income 43.6m / Total Assets 4.85b)
RoE = 26.13% (Net Income TTM 43.6m / Total Stockholder Equity 166.8m)
RoCE = 10.79% (EBIT 130.2m / Capital Employed (Equity 166.8m + L.T.Debt 1.04b))
RoIC = 11.44% (NOPAT 136.8m / Invested Capital 1.20b)
WACC = 8.97% (E(52.87b)/V(55.64b) * Re(9.35%) + D(2.77b)/V(55.64b) * Rd(1.60%) * (1-Tc(-0.05)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.43%
[DCF Debug] Terminal Value 66.38% ; FCFF base≈139.2m ; Y1≈91.4m ; Y5≈41.8m
Fair Price DCF = N/A (negative equity: EV 707.5m - Net Debt 1.28b = -575.6m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 72.77 | EPS CAGR: 39.58% | SUE: -2.44 | # QB: 0
Revenue Correlation: 90.99 | Revenue CAGR: 52.20% | SUE: 2.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.20 | Chg30d=-0.058 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=11.18 | Chg30d=+0.209 | Revisions Net=+2 | Growth EPS=+125.6% | Growth Revenue=+45.7%

Additional Sources for ALNY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle